Horizon Scanning Technology Briefing. Magnetic resonance spectroscopy for prostate cancer. National Horizon Scanning Centre.
|
|
- Douglas Miles
- 5 years ago
- Views:
Transcription
1 Horizon Scanning Technology Briefing National Horizon Scanning Centre Magnetic resonance spectroscopy for prostate cancer August 2006 This technology briefing is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes.
2 Magnetic resonance spectroscopy for prostate cancer Target group Identification and localisation of prostate cancer in men with elevated prostate specific antigen (PSA) or histopathology confirmed prostate cancer prior to prostatectomy. Technology description Magnetic resonance spectroscopy (MRS) is an add-on option to current high-field strength magnetic resonance imaging (MRI) systems. MRS measures the level of specific chemicals (including choline, creatine, citrate and lactate) in the targeted tissue. The MRS software displays a waveform with peaks corresponding to various chemicals being detected. By studying the relative quantities of chemicals in the tissue, cellular activity and the presence of malignant cells can be determined. Following a routine MR scan the MRS region of interest, called a voxel (typically a 1-2 cm cube of tissue), is targeted and the MRS waveform generated for that voxel. Some MRS systems can evaluate multiple voxels simultaneously. Data acquisition takes approximately 15 to 20 minutes. The technical quality of MRS information is improved using higher-field strength magnets (e.g. 1.0, 1.5 or 3.0 Tesla). MRS in men with prostate cancer has been undertaken in most published trials using an endorectal coil, which is invasive and can distort regional anatomy. MRS is used, or has been studied, in the diagnosis, evaluation and management of patients with brain tumours, strokes, oxygen deprivation, epilepsy and multiple sclerosis. High quality research evidence on diagnostic and clinical utility is scarce. 1,2 Innovation and/or advantages Expert opinion is that this technique could be used to detect cancer and perhaps reduce the need for biopsy in men with elevated PSA. Developer Add-on options to current MRI systems are available from several manufacturers including Siemens, Philips Medical Systems and GE Medical Systems. Purpose Diagnosis or identification of disease Prevention e.g. immunisation, public health programme Continuous therapy e.g. dialysis, life support Service delivery changes Investigation, assessment or staging of known disease Screening programme or tests to identify latent or early disease Patient management and pathways of care Other: Susceptibility testing for identifying risk of disease Individual treatment e.g. drug, device, procedure, radiotherapy Rehabilitation Place of use Home care e.g. home dialysis Secondary care e.g. general, non-specialist hospital General public e.g. over the counter Community or residential care e.g. district nurses, physio Tertiary care e.g. highly specialist services or hospital Other: Primary care e.g. used by GPs or practice nurses Emergency care e.g. paramedic services, trauma care Aug
3 Stage of development and availability in EU/UK Phase III clinical trials or Pre-registration in EU (drugs) equivalent Licence or CE mark application in Licence or CE mark application in UK/EU likely within 12 months UK/EU likely within 24 months Launch or use in UK/EU likely Established product, but this is a within 24 months new indication in development CE marked, but not yet launched or available in UK Launch or use in UK/EU likely within 12 months Other: already available in some centres. Add on MRS options will become more widespread in 2007/8 with newer MR machines installed under the cancer plan. Approval and/or availability in the USA and/or Canada Licensed for use in the USA Available for use in USA and/or and/or Canada Canada Details: Fast track designation in USA NHS or Government priority area: Cancer Cardiovascular disease Children Diabetes Chronic conditions Mental health Older people Public health Renal disease Women s health None identified Other: Relevant guidance A NICE clinical guideline on the diagnosis and treatment of prostate cancer is due to be published in November Clinical need and burden of disease The incidence of prostate cancer has been increasing, and in 2002 there were almost 28,000 men registered with prostate cancer in England and Wales. There were just over 9,000 deaths from prostate cancer in For men diagnosed in 2000 or 2001 the 5-year survival around 70%. Existing comparators and treatments Investigation of symptoms: PSA test; digital rectal examination (DRE); clinical examination of the abdomen and inguinal lymph nodes. Confirmation of diagnosis: prostate core needle biopsy for histopathology with transrectal ultrasound for visualisation. Staging and localisation: there are no accepted radiographic tests with a high enough specificity and sensitivity for reliable staging and localisation. CT scanning and MRI can be used, but accuracy can be poor and clinical utility is unknown. Nuclear imaging can be used to detect distant metastases. Clinical utility No published trials evaluating the clinical utility of MRS (i.e. the ability of MRS to change the patient care pathway or outcome) have been identified. Analytical and clinical validity A study in 48 men prior to radical prostatectomy compared MR alone, MR with MRS, and histopathology. 3 The study found false positive lesions associated with MR and MRS systems, and developed a decision rule based on lesion diameter and position to identify false positives. Aug
4 A study in 9 men who had increasing PSA after external-beam radiation therapy compared biopsy, DRE, MR and MRS as methods of identifying local prostate cancer recurrence. 4 MR spectroscopy had a sensitivity of 77% and a specificity of 78%. MR imaging had a sensitivity of 68% and a specificity of over 90%. MR spectroscopy was found to produce false positives. A study of MRS and MRS-guided prostate biopsy in 42 men with an elevated PSA and at least two negative prostate biopsies, found 31 men with metabolic abnormalities on MRS (voxel score 4: scale 1-benign to 5-malignant) suggestive of cancer. 5 Cancer was detected on MRS-guided biopsy in 17 of the 31 men giving a sensitivity of 100%, specificity 44%, positive predictive value 55%, and a negative predictive value 100%. A study of the additional benefit of MR and MRS when added to PSA- and histopathology-based nomograms in detecting prostate-confined cancer in 612 men prior to radical prostatectomy found that the addition of MR contributed significantly to the nomogram, particularly in those at intermediate or high-risk. 6 However, although the accuracy of the prediction was higher with the addition of MRS, the difference was not significant. An abstract of a study of non-invasive external coils for MRS (as opposed to endorectal coils) in 12 men with biopsy-proven prostate cancer, found in the 8 men with evaluable signals, a sensitivity and specificity of 78% and 57% respectively. 7 A study of the additional benefit of MR and MRS to clinical, PSA and histopathology scoring for detecting extracapsular extension of prostate cancer in 344 men prior to surgery, found that MR significantly added to the prediction, but MRS did not. 8 A study investigated the accuracy of a standardised evaluation tool for endorectal MRS in 37 men before radical prostatectomy. 9 Twenty-two had good or excellent MRS data and independent spectroscopists scored the spectra of selected voxels on a 5 point scale: 1 benign to 5-malignant. The specificity of voxel scores 4 and 5 were 84.6% and 89.3% respectively; and sensitivities 90% and 93%. The same patients were used in a study to evaluate the utility of MR and MRS in measuring tumour volume. 10 Tumour volume measurement using MR with MRS was significantly correlated with histolopathological volume post-surgery. The awareness of clinical data significantly improved the tumour detection rate of MRS. 11 A preliminary study of MR and MRS in 21 men with biochemical failure after external beam radiation therapy found that the presence of 3 or more suspicious voxels in a hemiprostate showed a sensitivity and specificity of 89% and 82% respectively for the diagnosis of local recurrence on later biopsy. 12 A case-controlled study evaluated the utility of combined MR and MRS in localising prostate cancer in 16 men receiving neoadjuvant hormone therapy prior to radical prostatectomy and 48 men not receiving hormone therapy prior to surgery. 13 Results showed that there was no difference in the sensitivity or specificity of MR and MRS between the hormone-treated and un-treated men. Aug
5 A study in 53 men with prostate cancer evaluated the validity of MR, MRS and combined MR/MRS in the detection and localisation of cancer. 14 Sensitivity of MR alone was 77% to 81%; specificity 61% to 46%. Sensitivity of MRS alone was significantly lower at 63%, and specificity significantly higher at 75%. Specificity was up to 91% for combined MR and MRS. Estimated cost and cost impact Expert estimates suggest that a MRI with spectroscopy would cost about 800 per scan. Potential or intended impact speculative Access to MR scanning time is a concern. Patients Reduced morbidity Quicker or more accurate diagnosis Reduced mortality or increased survival Earlier identification of disease Improved quality of life for patients and/or carers Changed pathway of care or outcome Services Increased use e.g. length of stay, out-patient visits Service reorganisation required Staff or training required Decreased use e.g. shorter length of stay, reduced Other: Increased access to MRI is required referrals Costs Increased unit cost compared to alternative Savings: Increased costs: more patients coming for treatment Other: Increased costs: capital investment needed References 1 Jordan HS, Bert R, Chew P, et al. Magnetic resonance spectroscopy for brain tumours. Prepared for the Agency for Healthcare Research and Quality. April Technology Evaluation Center. Magnetic resonance spectroscopy of revaluation of suspected brain tumor. Blue Cross and Blue Shield Association. Assessment Program 18(1) June Hom JJ, Coakley FV, Simko JP et al. Prostate cancer: endorectal MR imaging and MR spectroscopic imaging distinction of true-positive from chance-detected lesions. Radiology 2006;238: Pucar D, Shukla-Dave A, Hricak H et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy initial experience. Radiology 2005;236: Prando A, Kurhanewicz J, Borges A et al. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: initial experience. Radiology 2005;236: Wang L, Hricak H, Kattan MW et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imagine to staging nomograms. Radiology 2005;238: Hymel EC, Hyslop WB, Kwock L et al. Correlation of prostate MR spectroscopy using external pelvic phased coil assay to histopathology of prostatectomy specimens. American society of Clinical Oncology Abstract Wang L, Mullerad M, Chen HN et al. Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology 2004;232: Jung JA, Coakley FV, Vigneron DB et al. Prostate depiction at endorectal spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004;233: Coakley FV, Kurhanewicz J, Lu Y et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002;223: Dhingsa R, Qayyum A, Coakley FV et al. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology 2004;230: Aug
6 12 Coakley FV, The HS, Qayyum A et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 2004;233: Mueller-Lisse UG, Vigneron DB, Hricak H et al. Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1 H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology 2001;221: Scheidler J, Hricak H, Vigneron DB et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging clinicopathologic study. Radiology 1999;213: The is funded by the Research and Development Division of the Department of Health, England The, Department of Public Health and Epidemiology University of Birmingham, Edgbaston, Birmingham, B15 2TT, England Tel: +44 (0) Fax +44 (0) Aug
Horizon Scanning Technology Briefing National Helical Tomotherapy Horizon Hi-ART System for Scanning external cancer Centre radiotherapy August 2006
Horizon Scanning Technology Briefing National Horizon Scanning Centre Helical Tomotherapy Hi-ART System for external cancer radiotherapy August 2006 This technology briefing is based on information available
More informationHorizon Scanning Technology Briefing. Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer
Horizon Scanning Technology Briefing National Horizon Scanning Centre Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer December 2006 This technology summary is based on
More informationHorizon Scanning Technology Briefing. Alvimopan (Entrareg ) for opioid-induced bowel disfunction. National Horizon Scanning Centre.
Horizon Scanning Technology Briefing National Horizon Scanning Centre Alvimopan (Entrareg ) for opioid-induced bowel disfunction August 2006 This technology briefing is based on information available at
More informationHorizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma
Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology
More informationHorizon Scanning Technology Briefing. Cetuximab (Erbitux) for metastatic colorectal cancer. National Horizon Scanning Centre.
Horizon Scanning Technology Briefing National Horizon Scanning Centre Cetuximab (Erbitux) for metastatic colorectal cancer December 2006 This technology summary is based on information available at the
More informationHorizon Scanning Technology Summary. Magnetic resonance angiography (MRA) imaging for the detection of coronary artery disease
Horizon Scanning Technology Summary National Horizon Scanning Centre Magnetic resonance angiography (MRA) imaging for the detection of coronary artery disease April 2007 This technology summary is based
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer. December 2007
Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationCabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel
Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel April 2009 This technology summary is based on information available at the time of research and a
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationHorizon Scanning Technology Summary. Temozolomide (Temodal) for advanced metastatic melanoma. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Temozolomide (Temodal) for advanced metastatic melanoma April 2007 This technology summary is based on information available at the
More informationHorizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationHorizon Scanning Technology Summary. Methylnaltrexone for opioid induced constipation in advanced illness and palliative care
Horizon Scanning Technology Summary National Horizon Scanning Centre Methylnaltrexone for opioid induced constipation in advanced illness and palliative care April 2007 This technology summary is based
More informationNational Horizon Scanning Centre. Ampligen for chronic fatigue syndrome. December 2007
Ampligen for chronic fatigue syndrome December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationNational Horizon Scanning Centre. Azacitidine (Vidaza) for myelodysplastic syndrome. September 2007
Azacitidine (Vidaza) for myelodysplastic syndrome September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNational Horizon Scanning Centre. Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory. January 2008
Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory January 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationHorizon Scanning Technology Summary. Cyanocobalamin nasal spray (Nascobal) for vitamin B12 deficiency. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Cyanocobalamin nasal spray (Nascobal) for vitamin B12 deficiency April 2007 This technology summary is based on information available
More informationHorizon Scanning Technology Summary. Tenofovir disoproxil fumarate for hepatitis B. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Tenofovir disoproxil fumarate for hepatitis B April 2007 This technology summary is based on information available at the time of research
More informationNational Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationNational Horizon Scanning Centre. Rituximab (MabThera) for chronic lymphocytic leukaemia. September 2007
Rituximab (MabThera) for chronic lymphocytic leukaemia This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationStephen McManus, MD David Levi, MD
Stephen McManus, MD David Levi, MD Prostate MRI Indications INITIAL DETECTION, STAGING, RECURRENT TUMOR LOCALIZATION, RADIATION THERAPY PLANNING INITIAL DETECTION Clinically suspected prostate cancer before
More informationHorizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationNICE BULLETIN Diagnosis & treatment of prostate cancer
Diagnosis & treatment of prostate cancer NICE provided the content for this booklet which is independent of any company or product advertised Diagnosis and treatment of prostate cancer Introduction In
More informationEribulin for locally advanced or metastatic breast cancer third line; monotherapy
Eribulin for locally advanced or metastatic breast cancer third line; monotherapy April 2009 This technology summary is based on information available at the time of research and a limited literature search.
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationThe Role of Combined MRI & MRSI in Treating Prostate Cancer
The Role of Combined MRI & MRSI in Treating Prostate Cancer By the Prostate Cancer MRI/MRSI Group (Penelope Wood, BS, John Kurhanewicz, Ph.D., Daniel Vigneron, Ph.D., Mark Swanson, Ph.D., and Saying Li,
More informationRilonacept for cryopyrin associated periodic syndromes
Rilonacept for cryopyrin associated periodic syndromes August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationPROSTATE MRI. Dr. Margaret Gallegos Radiologist Santa Fe Imaging
PROSTATE MRI Dr. Margaret Gallegos Radiologist Santa Fe Imaging Topics of today s talk How does prostate MRI work? Definition of multiparametric (mp) MRI Anatomy of prostate gland and MRI imaging Role
More informationNational Breast Cancer Audit next steps. Martin Lee
National Breast Cancer Audit next steps Martin Lee National Cancer Audits Current Bowel Cancer Head & Neck Cancer Lung cancer Oesophagogastric cancer New Prostate Cancer - undergoing procurement Breast
More informationNIH Public Access Author Manuscript Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2013 April 1.
NIH Public Access Author Manuscript Published in final edited form as: Int J Radiat Oncol Biol Phys. 2012 April 1; 82(5): e787 e793. doi:10.1016/j.ijrobp.2011.11.030. Does local recurrence of prostate
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008
Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationOne Stop Prostate Biopsy Protocol Author Consultation Date Approved
One Stop Prostate Biopsy Protocol Author Consultation Date Approved Urology Nurse Practioner PROTOCOL FOR MEN ATTENDING A ONE STOP PROSTATE BIOPSY CLINIC RATIONALE Prostate cancer is the most common cancer
More informationNational Prostate Cancer Audit. Bill Cross June 2015
National Prostate Cancer Audit Bill Cross June 2015 National Prostate Cancer Audit aim of assessing the process of care and its outcomes in men diagnosed with prostate cancer in England and Wales National
More informationNational Horizon Scanning Centre. Dronedarone (Multaq) for atrial fibrillation and atrial flutter. December 2007
Dronedarone (Multaq) for atrial fibrillation and atrial flutter December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationNational Horizon Scanning Centre. Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours. August 2008
Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours August 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationNational Horizon Scanning Centre. Pregabalin (Lyrica) for fibromyalgia. September 2007
Pregabalin (Lyrica) for fibromyalgia September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationNational Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007
Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationLouisa Fleure. Advanced Prostate Cancer Clinical Nurse Specialist. Guys and St Thomas NHS Trust
Louisa Fleure Advanced Prostate Cancer Clinical Nurse Specialist Guys and St Thomas NHS Trust The classification of advanced prostate cancer The incidence of patients presenting with, or developing advanced
More informationAppendix 4 Urology Care Pathways
Appendix 4 Urology Care Pathways Cancer Care Pathways outline the steps and stages in the patient journey from referral through to diagnostics, staging, treatment, follow up, rehabilitation and if applicable
More informationDiffusion-Weighted Magnetic Resonance Imaging Detects Local Recurrence After Radical Prostatectomy: Initial Experience
EUROPEAN UROLOGY 61 (2012) 616 620 available at www.sciencedirect.com journal homepage: www.europeanurology.com Case Study of the Month Diffusion-Weighted Magnetic Resonance Imaging Detects Local Recurrence
More informationPatient Information. Prostate Tissue Ablation. High Intensity Focused Ultrasound for
High Intensity Focused Ultrasound for Prostate Tissue Ablation Patient Information CAUTION: Federal law restricts this device to sell by or on the order of a physician CONTENT Introduction... 3 The prostate...
More informationLow risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer
Evidence-based utilization of imaging in prostate cancer Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Objectives State the modalities,
More informationNational Horizon Scanning Centre. Decitabine (Dacogen) for myelodysplastic syndrome. April 2008
Decitabine (Dacogen) for myelodysplastic syndrome April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be
More informationNational Horizon Scanning Centre. GV1001 for advanced and/or metastatic pancreatic cancer. April 2008
GV1001 for advanced and/or metastatic pancreatic cancer April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationCabozantinib for medullary thyroid cancer. February 2012
Cabozantinib for medullary thyroid cancer February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationLouisa Fleure. Advanced Prostate Cancer Clinical Nurse Specialist. Guys and St Thomas NHS Trust
Louisa Fleure Advanced Prostate Cancer Clinical Nurse Specialist Guys and St Thomas NHS Trust The classification of advanced prostate cancer The incidence of patients presenting with, or developing advanced
More informationThe utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis
Original Article PREDICTING INSIGNIFICANT PROSTATE CANCER WITH MRI AND CLINICAL VARIABLES SHUKLA-DAVE ET AL. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationB-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma
B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is
More informationNational Horizon Scanning Centre. Transient elastography (FibroScan) for evaluating liver fibrosis. April 2008
Transient elastography (FibroScan) for evaluating liver fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008
Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationNational Horizon Scanning Centre. Methylnaltrexone (MOA-728) for postoperative ileus. April 2008
(MOA-728) for postoperative ileus April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationClinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate
Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate Reference: NHS England B01X09 First published: March 2016 Prepared by NHS England Specialised Services Clinical
More informationThe European Board of Urology
Page 1 of 15 The European Board of Urology Sub-specialty certification application: Prostate cancer, A - General information A1 - APPLICATION IDENTIFICATION 1a. Application code blank 1b. EBU internal
More informationNational Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008
Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationProstate MRI: Who needs it?
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationMRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review
MRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review Poster No.: C-1208 Congress: ECR 2014 Type: Educational Exhibit Authors: J. Murphy, M.
More informationSubject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection
More informationProposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram
Proposed All Wales Vulval Cancer Guidelines Dr Amanda Tristram Previous FIGO staging FIGO Stage Features TNM Ia Lesion confined to vulva with
More informationNational Horizon Scanning Centre. Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment
Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment April 2008 This technology summary is based on information available at the time of research and
More informationInsulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children
Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children December 2008 This technology summary is based on information available at the time of research and a limited literature
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationGuidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationGuidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationRadiology. General radiology department. X-ray
The radiology directorate provides a diagnostic, interventional and therapeutic service for its local population, and a tertiary service for the region. It also provides support to some national work such
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationNational Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationTechnology appraisal guidance Published: 21 November 2018 nice.org.uk/guidance/ta546
Padeliporfin for untreated localised prostate cancer Technology appraisal guidance Published: 21 November 2018 nice.org.uk/guidance/ta546 NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationEverolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery
Everolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery April 2011 This technology summary is based on information
More informationA schematic of the rectal probe in contact with the prostate is show in this diagram.
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationOlesoxime for amyotrophic lateral sclerosis first line
Olesoxime for amyotrophic lateral sclerosis first line May 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationWhat Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).
What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). It is a very common cancer in men; some cancers grow very slowly,
More informationPeripheral Zone Prostate Cancer in Patients with Elevated PSA Levels and Low Free-to-Total PSA Ratio: Detection with MR Imaging and MR Spectroscopy
Página 1 de 12 Peripheral Zone Prostate Cancer in Patients with Elevated PSA Levels and Low Free-to-Total PSA Ratio: Detection with MR Imaging and MR Spectroscopy Joan C. Vilanova,, MD, PhD, Josep Comet,,
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation
Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of
More informationD. J. Margolis 1, S. Natarajan 2, D. Kumar 3, M. Macairan 4, R. Narayanan 3, and L. Marks 4
Biopsy Tracking and MRI Fusion to Enhance Imaging of Cancer Within the Prostate D. J. Margolis 1, S. Natarajan 2, D. Kumar 3, M. Macairan 4, R. Narayanan 3, and L. Marks 4 1 Dept. of Radiology, UCLA, Los
More informationTHE PROSTATE. SMALL GLAND BIG PROBLEM By John Crow. Chapter 4
THE PROSTATE SMALL GLAND BIG PROBLEM By John Crow Chapter 4 In this chapter I want to address the big issue CANCER. What is CANCER? As you will already know, our body tissue is made up of literally Billions
More informationLocally Advanced Prostate Cancer: Three-Dimensional Magnetic Resonance Spectroscopy to Monitor Prostate Response to Therapy
International Journal of Radiation Oncology biology physics www.redjournal.org Clinical Investigation: Genitourinary Cancer Locally Advanced Prostate Cancer: Three-Dimensional Magnetic Resonance Spectroscopy
More informationFieldStrength. Multi-parametric 3.0T MRI provides excellent prostate imaging
FieldStrength Publication for the Philips MRI Community Issue 35 September / October 2008 Multi-parametric 3.0T MRI provides excellent prostate imaging Three different centers show that advances in imaging
More informationProstate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144
Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144 Objectives: Detection of prostate cancer the need for better imaging What
More informationCancer of Unknown Primary (CUP)
Cancer of Unknown Primary (CUP) Pathways and Guidelines V1.0 London Cancer September 2013 The following pathways and guidelines document has been compiled by the London Cancer CUP technical subgroup and
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationNational Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008
Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class April 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationDiffusion-Weighted Imaging of Prostate Cancer
ORIGINAL ARTICLE Diffusion-Weighted Imaging of Prostate Cancer Ryota Shimofusa, MD,* Hajime Fujimoto, MD, Hajime Akamata, MD, Ken Motoori, MD,* Seiji Yamamoto, MD,* Takuya Ueda, MD,* and Hisao Ito, MD*
More informationLocalized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA
Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA ESMO Cape Town 14 Feb 2018 Disclosures Advisory boards/lecturer/consultant-
More informationADVICE TO PATIENTS REQUESTING PSA MEASUREMENT
Frequently-Asked Questions What is the aim of this leaflet? Prostate cancer is a serious condition. The PSA test, which can give an early indication of prostate cancer, is available to you if you want
More informationGene Expression Profiling has been proposed as a method of risk stratification for uveal melanoma.
Last Review Status/Date: September 2014 Description Page: 1 of 5 Gene Expression Profiling has been proposed as a method of risk stratification for uveal melanoma. Background Uveal melanoma Uveal melanoma,
More information11/10/2015. Prostate cancer in the U.S. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning. NIH estimates for 2015.
Multi-parametric MRI of Prostate Diagnosis and Treatment Planning Temel Tirkes, M.D. Associate Professor of Radiology Director, Genitourinary Radiology Indiana University School of Medicine Department
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationGeneral information about prostate cancer
Prostate Cancer General information about prostate cancer Key points Prostate cancer is a disease in which malignant (cancer) cells form in the tissues of the prostate. Signs of prostate cancer include
More information